Published online before print September 7, 2006, doi: 10.1161/01.ATV.0000244681.72738.bc
© 2006 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis
From CVPath Institute, Inc (F.D.K., A.P.B., K.S.S., E.L., R.K., R.V.), Gaithersburg, Md; and the Department of Pathology (A.T.M.), Georgetown University, Washington, DC.
Correspondence to Renu Virmani, MD, Medical Director, CVPath Institute Inc, 19 Firstfield Road, Gaithersburg, MD 20878. E-mail rvirmani{at}cvpath.org
Objective— Although lipoprotein-associated phospholipase A2 (Lp-PLA2) has received recent attention as a biomarker of inflammation and risk for acute coronary events, its relative expression in coronary plaque phenotypes, including unstable lesions, has not been established.
Methods and Results— Coronary segments (n=30) were prospectively collected from 25 sudden coronary death patients for immunolocalization of Lp-PLA2. Lesion morphologies were classified as pathologic intimal thickening, fibroatheromas, thin-cap fibroatheromas (fibrous cap thicknesses <65 µm), and rupture. The expression of Lp-PLA2 was detected using a specific monoclonal antibody. Apoptosis was identified by DNA end-labeling using terminal deoxynucleotidyl transferase (TdT). Lp-PLA2 staining in early plaques was absent or minimally detected. In contrast, thin-cap fibroatheromas and ruptured plaques showed intense Lp-PLA2 expression within necrotic cores and surrounding macrophages including those in the fibrous cap. The degree of macrophage apoptosis was greater in thin-cap fibroatheroma and ruptures compared with less advanced plaques with additional double labeling studies showing Lp-PLA2 present in apoptotic cells in regions of high macrophage density.
Conclusions— Lp-PLA2 is strongly expressed within the necrotic core and surrounding macrophages of vulnerable and ruptured plaques, with relatively weak staining in less advanced lesions. These findings together with the association of Lp-PLA2 in apoptotic macrophages suggest a potential role in promoting plaque instability.
The expression of lipoprotein-associated phospholipase A2 (Lp-PLA2) was assessed in early through late, unstable coronary plaques from sudden death victims. Lp-PLA2 was mostly present in plaque ruptures and thin-cap fibroatheromas in necrotic cores and surrounding areas of apoptotic macrophages. The present study suggests Lp-PLA2 may be an important biomarker for plaque instability.
Key Words: lipoprotein-associated phospholipase A2 • sudden coronary death • plaque rupture • apoptosis • cardiovascular risk
Related Article:
Arterioscler Thromb Vasc Biol 2006 26: 2417-2418.
This article has been cited by other articles:
 |
|
 |
|
  C. B. Wright, Y. Moon, M. C. Paik, T. R. Brown, L. Rabbani, M. Yoshita, C. DeCarli, R. Sacco, and M. S.V. Elkind Inflammatory Biomarkers of Vascular Risk as Correlates of Leukoariosis Stroke, November 1, 2009; 40(11): 3466 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C.A. Kramer, S. Z.H. Rittersma, R. J. de Winter, E. R. Ladich, D. R. Fowler, Y.-H. Liang, R. Kutys, N. Carter-Monroe, F. D. Kolodgie, A. C. van der Wal, et al. Relationship of Thrombus Healing to Underlying Plaque Morphology in Sudden Coronary Death J. Am. Coll. Cardiol., October 7, 2009; (2009) j.jacc.2009.09.007v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Vickers, C. T. Maguire, R. Wolfert, A. R. Burns, M. Reardon, R. Geis, P. Holvoet, and J. D. Morrisett Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis J. Lipid Res., September 1, 2009; 50(9): 1735 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Suzuki, C. Solomon, N. S. Jenny, R. Tracy, J. J. Nelson, B. M. Psaty, C. Furberg, and M. Cushman Lipoprotein-Associated Phospholipase A2 and Risk of Congestive Heart Failure in Older Adults: The Cardiovascular Health Study Circ Heart Fail, September 1, 2009; 2(5): 429 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Munzel and T. Gori Lipoprotein-associated phospholipase A2, a marker of vascular inflammation and systemic vulnerability Eur. Heart J., August 30, 2009; (2009) ehp311v1. [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann, D. Mannheim, C. Wohlert, D. Versari, F. B. Meyer, J. P. McConnell, M. Gossl, L. O. Lerman, and A. Lerman Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome Eur. Heart J., August 17, 2009; (2009) ehp309v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Sluimer, F. D. Kolodgie, A. P.J.J. Bijnens, K. Maxfield, E. Pacheco, B. Kutys, H. Duimel, P. M. Frederik, V. W.M. van Hinsbergh, R. Virmani, et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1517 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Virmani, A. V. Finn, and F. D. Kolodgie Carotid Plaque Stabilization and Progression After Stroke or TIA Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 3 - 6. [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, J. Willeit, M. Knoflach, M. Mayr, G. Egger, M. Notdurfter, J. L. Witztum, C. J. Wiedermann, Q. Xu, and S. Kiechl Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study Eur. Heart J., January 1, 2009; 30(1): 107 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. McConnell and A. S. Jaffe The Spin Stops Here: Inhibition of Lipoprotein-Associated Phospholipase A2-- A Promising Target but a Negative Initial Trial? Clin. Chem., January 1, 2009; 55(1): 21 - 23. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Boekholdt, R. J. de Winter, and J. J.P. Kastelein Inhibition of Lipoprotein-Associated Phospholipase Activity by Darapladib: Shifting Gears in Cardiovascular Drug Development: Are Antiinflammatory Drugs the Next Frontier? Circulation, September 9, 2008; 118(11): 1120 - 1122. [Full Text] [PDF]
|
|
|
|
|
|
P. W. Serruys, H. M. Garcia-Garcia, P. Buszman, P. Erne, S. Verheye, M. Aschermann, H. Duckers, O. Bleie, D. Dudek, H. E. Botker, et al. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque Circulation, September 9, 2008; 118(11): 1172 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Gardner, E. C. Reichert, M. K. Topham, and D. M. Stafforini Identification of a Domain That Mediates Association of Platelet-activating Factor Acetylhydrolase with High Density Lipoprotein J. Biol. Chem., June 20, 2008; 283(25): 17099 - 17106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Sutton, D. R. Crosslin, S. H. Shah, S. C. Nelson, A. Bassil, A. B. Hale, C. Haynes, P. J. Goldschmidt-Clermont, J. M. Vance, D. Seo, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets Hum. Mol. Genet., May 1, 2008; 17(9): 1318 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mannheim, J. Herrmann, D. Versari, M. Gossl, F. B. Meyer, J. P. McConnell, L. O. Lerman, and A. Lerman Enhanced Expression of Lp-PLA2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques Stroke, May 1, 2008; 39(5): 1448 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Mohler III, C. M. Ballantyne, M. H. Davidson, M. Hanefeld, L. M. Ruilope, J. L. Johnson, A. Zalewski, and for the Darapladib Investigators The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1632 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wassertheil-Smoller, C. Kooperberg, A. P. McGinn, R. C. Kaplan, J. Hsia, S. L. Hendrix, J. E. Manson, J. S. Berger, L. H. Kuller, M. A. Allison, et al. Lipoprotein-Associated Phospholipase A2, Hormone Use, and the Risk of Ischemic Stroke in Postmenopausal Women Hypertension, April 1, 2008; 51(4): 1115 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Davis, G. Koster, L. J. Douet, M. Scigelova, G. Woffendin, J. M. Ward, A. Smith, J. Humphries, K. G. Burnand, C. H. Macphee, et al. Electrospray Ionization Mass Spectrometry Identifies Substrates and Products of Lipoprotein-associated Phospholipase A2 in Oxidized Human Low Density Lipoprotein J. Biol. Chem., March 7, 2008; 283(10): 6428 - 6437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Daniels, G. A. Laughlin, M. J. Sarno, R. Bettencourt, R. L. Wolfert, and E. Barrett-Connor Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, D. A. Morrow, M. O'Donoghue, K. A. Jablonksi, M. M. Rice, S. Solomon, Y. Rosenberg, M. J. Domanski, J. Hsia, and for the PEACE Investigators Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2463 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, L. D. Tsironis, and A. D. Tselepis New Insights Into the Role of Lipoprotein(a)-Associated Lipoprotein-Associated Phospholipase A2 in Atherosclerosis and Cardiovascular Disease Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2094 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Oorni and P. T. Kovanen PLA2-V: A Real Player in Atherogenesis Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 445 - 447. [Full Text] [PDF]
|
|
|
|
|
|
N. S. Jenny Lipoprotein-associated phospholipase A2: novel biomarker and causal mediator of atherosclerosis? Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2417 - 2418. [Full Text] [PDF]
|
|